Trial Profile

Phase 2 study of MZE001 Pompe disease patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MZE 001 (Primary)
Indications Glycogen storage disease type II
Focus Therapeutic Use

Most Recent Events

10 May 2024 According to Shionogi media release, Shionogi & Co., Ltd. and Maze Therapeutics, Inc. announce exclusive worldwide license agreement for MZE001, a novel therapeutic candidate for the treatment of Pompe Disease.
22 Mar 2023 According to a Maze Therapeutics media release, the company look forward to beginning this Phase 2 trial later this year.
01 Sep 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com